Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
James Heyes

James Heyes

Chief Executive Officer, Genevant Sciences

Appears in 1 story

Notable Quotes

"The settlement allows us to put this lengthy dispute behind us. At the same time, it is enormously gratifying for the Genevant team to, at long last, be recognized for our pivotal contribution to restoring normalcy around the world in the face of a once-in-a-lifetime pandemic." — Statement on March 3, 2026

Stories

Moderna's battle over the delivery technology in its COVID vaccine

Rule Changes

Settlement reached

For four years, the question of whether Moderna owed billions for technology at the heart of its COVID-19 vaccine hung over the company. Less than a week before a jury trial was set to begin in Delaware, Moderna agreed to pay up to $2.25 billion to settle patent claims brought by Arbutus Biopharma and Genevant Sciences—accepting a court judgment that it infringed four patents and that those patents are valid. If the full amount is paid, it would be the largest disclosed patent settlement in pharmaceutical history, surpassing a $2.15 billion Pfizer-Takeda settlement in 2013.

Updated Mar 4